keyword
MENU ▼
Read by QxMD icon Read
search

survival improvement in patients with pancreatic cancer

keyword
https://www.readbyqxmd.com/read/29777994/analysis-of-incidence-mortality-and-survival-for-pancreatic-and-biliary-tract-cancers-across-europe-with-assessment-of-influence-of-revised-european-age-standardisation-on-estimates
#1
Pamela Minicozzi, Tiziana Cassetti, Claudia Vener, Milena Sant
BACKGROUND: Pancreatic (PC) and biliary tract (BTC) cancers have higher incidence and mortality in Europe than elsewhere. We analysed time-trends in PC/BTC incidence, mortality, and survival across Europe. Since the European standard population (ESP) was recently revised to better represent European age structure, we also assessed the effect of adopting the revised ESP to age-standardise incidence and mortality data. METHODS: We analysed PCs/BTCs (≥15 years) diagnosed in 2000-2007 and followed-up to end of 2008, in 29 European countries across five regions: UK/Ireland, and northern, central, southern, and eastern Europe...
May 16, 2018: Cancer Epidemiology
https://www.readbyqxmd.com/read/29771771/a-therapeutic-strategy-for-resectable-pancreatic-cancer-based-on-risk-factors-of-early-recurrence
#2
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Yuko Kijima, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe
OBJECTIVES: The aim of this study was to identify risk factors for early recurrence and assess the prognostic benefit of neoadjuvant therapy (NAT) for resectable pancreatic cancer. METHODS: Patients with radiographically resectable pancreatic cancer according to the National Comprehensive Cancer Network guidelines were enrolled. We regarded recurrence within 6 months after surgery as early recurrence. RESULTS: This study involved 115 patients (80 who underwent upfront surgery and 35 who received NAT)...
May 15, 2018: Pancreas
https://www.readbyqxmd.com/read/29731985/association-between-homologous-recombination-repair-gene-mutations-and-response-to-oxaliplatin-in-pancreatic-cancer
#3
Tomohiro Kondo, Masashi Kanai, Tadayuki Kou, Tomohiro Sakuma, Hiroaki Mochizuki, Mayumi Kamada, Masahiko Nakatsui, Norimitsu Uza, Yuzo Kodama, Toshihiko Masui, Kyoichi Takaori, Shigemi Matsumoto, Hidehiko Miyake, Yasushi Okuno, Manabu Muto
Objectives: We aimed to examine the association between homologous recombination repair (HRR)-related gene mutations and efficacy of oxaliplatin-based chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Results: Non-synonymous mutations in HRR-related genes were found in 13 patients and only one patient had a family history of pancreatic cancer. Eight patients with HRR-related gene mutations (group A) and nine without HRR-related gene mutations (group B) received oxaliplatin-based chemotherapy...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29721665/status-and-future-directions-in-the-management-of-pancreatic-cancer-potential-impact-of-nanotechnology
#4
REVIEW
Catherine M Sielaff, Shaker A Mousa
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at a late stage, has limited treatments, and patients have poor survival rates. It currently ranks as the seventh leading cause of cancer deaths globally and has increasing rates of diagnosis. Improved PDAC treatment requires the development of innovative, effective, and economical therapeutic drugs. The late stage diagnosis limits options for surgical resection, and traditional PDAC chemotherapeutics correlate with increased organ and hematologic toxicity...
May 2, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29721211/advanced-pancreatic-cancer-a-meta-analysis-of-clinical-trials-over-thirty-years
#5
Bradley R Hall, Andrew Cannon, Pranita Atri, Christopher S Wichman, Lynette M Smith, Apar K Ganti, Chandrakanth Are, Aaron R Sasson, Sushil Kumar, Surinder K Batra
Background: In contrast to other cancers, survival rates for pancreatic ductal adenocarcinoma (PDAC) patients have improved but minimally over the past thirty years. The aim of this study was to perform a meta-analysis of clinical trials published since 1986 to determine trends in median overall survival in primarily metastatic PDAC. Materials and methods: All Phase 2-4 clinical trials published during or after 1986 investigating first-line systemic chemotherapy in metastatic PDAC were included in the meta-analysis...
April 10, 2018: Oncotarget
https://www.readbyqxmd.com/read/29719602/leptin-notch-axis-impairs-5-fluorouracil-effects-on-pancreatic-cancer
#6
Adriana Harbuzariu, Ruben Rene Gonzalez-Perez
5-FU chemotherapy is a current strategy to treat pancreatic cancer (PC), but unfortunately chemoresistance is eventually developed in most patients. Obesity is a risk factor for PC that could affect 5-FU effectiveness through the adipokine leptin, which is a known proliferation, survival factor and Notch inducer. We investigated whether leptin signaling affects 5-FU cytotoxicity on PC. To this end, tumorspheres developed from BxPC-3 and MiaPaCa-2 PC cells were treated with 5-FU, leptin, inhibitors for Notch (DAPT) and leptin signaling (IONP-LPrA2) and ATP-binding cassette of proteins (Probenecid)...
April 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29719589/combination-of-interferon-expressing-oncolytic-adenovirus-with-chemotherapy-and-radiation-is-highly-synergistic-in-hamster-model-of-pancreatic-cancer
#7
Amanda O Salzwedel, Joohee Han, Christopher J LaRocca, Ryan Shanley, Masato Yamamoto, Julia Davydova
Recent clinical trials utilizing Interferon-alpha (IFN) in combination with chemoradiation have demonstrated significant improvements in the survival of patients with pancreatic cancer. However, efficacy was limited by the systemic toxicity of IFN and low intratumoral levels of the cytokine. We sought to address these drawbacks by using an Oncolytic Adenovirus expressing IFN (OAd-hamIFN) in combination with chemotherapy and/or radiation in regimens mimicking the IFN-based therapies used in clinical trials. IFN expressed from OAd-hamIFN potentiated the cytotoxicity of radiation and chemotherapy (5-FU, Gemcitabine, and Cisplatin), and enhanced pancreatic cancer cell death in both in vitro and in vivo experimental settings...
April 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29718363/efficacy-and-safety-comparison-of-nabpaclitaxel-plus-s-1-and-gemcitabine-plus-s-1-as-first-line-chemotherapy-for-metastatic-pancreatic-cancer
#8
Yaolin Xu, Xi Guo, Yue Fan, Dansong Wang, Wenchuan Wu, Lili Wu, Tianshu Liu, Bei Xu, Yi Feng, Yan Wang, Wenhui Lou, Yuhong Zhou
Objective: To compare efficacy and safety of nabpaclitaxel plus S-1 (AS) with gemcitabine plus S-1 (GS) as first-line treatment for metastatic pancreatic cancer. Methods: We conducted a retrospective cohort, single-institution analysis by reviewing medical records of 38 patients who received either AS (nabpaclitaxel 125 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) or GS (gemcitabine 1000 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) chemotherapy. Results: AS was associated with a prolonged median time to progression (TTP; 7...
April 28, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29717230/therapeutic-developments-in-pancreatic-cancer-current-and-future-perspectives
#9
REVIEW
John P Neoptolemos, Jörg Kleeff, Patrick Michl, Eithne Costello, William Greenhalf, Daniel H Palmer
The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the next decade in Western countries. The past few years, however, have seen improvements in first-line and second-line palliative therapies and considerable progress in increasing survival with adjuvant treatment. The use of biomarkers to help define treatment and the potential of neoadjuvant therapies also offer opportunities to improve outcomes...
May 1, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29708592/meta-analysis-comparing-upfront-surgery-with-neoadjuvant-treatment-in-patients-with-resectable-or-borderline-resectable-pancreatic-cancer
#10
REVIEW
E Versteijne, J A Vogel, M G Besselink, O R C Busch, J W Wilmink, J G Daams, C H J van Eijck, B Groot Koerkamp, C R N Rasch, G van Tienhoven
BACKGROUND: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer. METHODS: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment...
April 30, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29707526/combination-immunotherapy-approaches-for-pancreatic-cancer-treatment
#11
REVIEW
Xianliang Cheng, Gang Zhao, Yunqi Zhao
Pancreatic ductal adenocarcinoma is a lethal malignant disease with a very low medium survival. Currently, metastatic pancreatic cancer poorly responds to conventional treatments and exhibits an acute resistance to most chemotherapy. Few approaches have been shown to be effective for metastatic pancreatic cancer treatment. Novel therapeutic approaches to treat patients with pancreatic adenocarcinoma are in great demand. Last decades, immunotherapies have been evaluated in clinical trials and received great success in many types of cancers...
2018: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29685122/treatment-of-pancreatic-ductal-adenocarcinoma-with-tumor-antigen-specific-targeted-delivery-of-paclitaxel-loaded-plga-nanoparticles
#12
Shu-Ta Wu, Anthony J Fowler, Corey B Garmon, Adam B Fessler, Joshua D Ogle, Kajal R Grover, Bailey C Allen, Chandra D Williams, Ru Zhou, Mahboubeh Yazdanifar, Craig A Ogle, Pinku Mukherjee
BACKGROUND: Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancers with a 5-year survival below 10%. Systemic delivery of chemotherapy drugs has severe side effects in patients with PDA and does not significantly improve overall survival rate. It is highly desirable to advance the therapeutic efficacy of chemotherapeutic drugs by targeting their delivery and increasing accumulation at the tumor site. MUC1 is a membrane-tethered glycoprotein that is aberrantly overexpressed in > 80% of PDA thus making it an attractive antigenic target...
April 23, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29683970/endoscopic-ultrasound-based-pancreatic-cancer-screening-of-high-risk-individuals-a-prospective-observational-trial
#13
Alexandra Gangi, Mokenge Malafa, Jason Klapman
OBJECTIVES: Pancreatic cancer (PC), a common cause of cancer death, is rarely diagnosed at an early stage. Early detection of PC may improve outcomes in affected patients. This study evaluated the utility of screening of high-risk individuals (HRIs) using an endoscopic ultrasound (EUS)-only approach to detect early malignant changes. METHODS: A prospective PC screening program for HRIs was opened in 2007. Fifty-eight patients have enrolled to date. Patients with normal EUS examinations underwent repeat EUS annually for 5 years...
April 19, 2018: Pancreas
https://www.readbyqxmd.com/read/29680448/the-role-of-intraoperative-radiotherapy-iort-in-the-management-of-patients-with-pancreatic-and-periampullary-cancer-a-single-center-experience
#14
Ayman Zaki Azzam, Ahmed Alqarni, Tarek Mahmoud Amin
BACKGROUND: In spite of the advances in modern surgery, the outcome for patients suffering from pancreatic adenocarcinoma or periampullary adenocarcinoma is still bad. Recently, introperative radiotherapy (IORT) was introduced into the multimodality management approach to improve both tumor control and patient' survival. AIM OF WORK: To evaluate our initial experience in combined surgical resection and IORT, and to evaluate the feasibility of the application of IORT and its effect on morbidity, mortality and local recurrence...
April 18, 2018: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/29677073/outcomes-after-cardiac-transplant-for-wild-type-transthyretin-amyloidosis
#15
Andrew N Rosenbaum, Omar F Abou Ezzeddine, Martha Grogan, Angela Dispenzieri, Sudhir Kushwaha, Alfredo Clavell, Richard C Daly, Brooks S Edwards
BACKGROUND: The true prevalence of heart failure (HF) due to wild type transthyretin amyloidosis (ATTRwt) is likely underestimated. There is a paucity of data with regard to the management of ATTRwt-related advanced HF and the natural history of extracardiac ATTRwt. METHODS: We conducted a retrospective cohort study of patients undergoing cardiac transplant (HTx) for ATTRwt at a single institution. Comprehensive clinical data, including baseline hemodynamic and echocardiographic characteristics, and posttransplant outcomes were obtained...
April 19, 2018: Transplantation
https://www.readbyqxmd.com/read/29675033/identification-and-validation-of-a-diagnostic-and-prognostic-multi-gene-biomarker-panel-for-pancreatic-ductal-adenocarcinoma
#16
Hagen Klett, Hannah Fuellgraf, Ella Levit-Zerdoun, Saskia Hussung, Silke Kowar, Simon Küsters, Peter Bronsert, Martin Werner, Uwe Wittel, Ralph Fritsch, Hauke Busch, Melanie Boerries
Late diagnosis and systemic dissemination essentially contribute to the invariably poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Therefore, the development of diagnostic biomarkers for PDAC are urgently needed to improve patient stratification and outcome in the clinic. By studying the transcriptomes of independent PDAC patient cohorts of tumor and non-tumor tissues, we identified 81 robustly regulated genes, through a novel, generally applicable meta-analysis. Using consensus clustering on co-expression values revealed four distinct clusters with genes originating from exocrine/endocrine pancreas, stromal and tumor cells...
2018: Frontiers in Genetics
https://www.readbyqxmd.com/read/29665327/adjuvant-radiotherapy-and-chemotherapy-improve-survival-in-patients-with-pancreatic-adenocarcinoma-receiving-surgery-adjuvant-chemotherapy-alone-is-insufficient-in-the-era-of-intensity-modulation-radiation-therapy
#17
Mao-Chih Hsieh, Wei-Wen Chang, Hsin-Hsien Yu, Chang-Yun Lu, Chia-Lun Chang, Jyh-Ming Chow, Shee-Uan Chen, Yunfeng Cheng, Szu-Yuan Wu
In the era of intensity modulation radiation therapy (IMRT), no prospective randomized trial has evaluated the efficacy of adjuvant therapies such as adjuvant concurrent chemoradiotherapy (CCRT), adjuvant sequential chemotherapy and radiotherapy (CT-RT), and adjuvant CT alone in resectable pancreatic adenocarcinoma (PA). Through propensity score matching, we designed a nationwide, population-based, head-to-head cohort study to determine the effects of dissimilar adjuvant treatments on resectable PA. We minimized the confounding of various adjuvant treatment outcomes among the following resectable PA groups of patients from the Taiwan Cancer Registry database: group 1, adjuvant CCRT; group 2, adjuvant sequential CT-RT; and group 3, adjuvant CT alone...
April 17, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29662668/proteomic-biomarkers-in-body-fluids-associated-with-pancreatic-cancer
#18
REVIEW
Cristina Jimenez-Luna, Carolina Torres, Raul Ortiz, Carmelo Dieguez, Joaquina Martinez-Galan, Consolacion Melguizo, Jose C Prados, Octavio Caba
Pancreatic cancer (PC) is a highly malignant disease that represents the fourth leading cancer-related death worldwide. There has been very little improvement in survival rates over recent years, and surgical resection remains the only reliable curative approach. Factors that contribute to this dismal prognosis for PC include its rapid progression and invasion, the absence of specific symptoms, and the little impact of available chemotherapy. Importantly, the management of this malignancy is also limited by the lack of highly specific and sensitive biomarkers for its diagnosis and follow-up, and their identification is therefore considered a promising strategy to improve outcomes in these patients...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29651946/neoadjuvant-therapy-is-essential-for-resectable-pancreatic-cancer
#19
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Shuo Li, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
BACKGROUND: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. METHODS: In this review, we examined available data on neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials...
April 12, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29651809/development-of-chemotherapy-and-significance-of-conversion-surgery-after-chemotherapy-in-unresectable-pancreatic-cancer
#20
REVIEW
Junji Furuse, Junji Shibahara, Masanori Sugiyama
While surgery currently remains the only potentially curative treatment available for pancreatic cancer, only 20% to 30% of patients have resectable disease at diagnosis. Recently, with the introduction of intensive chemotherapy regimens such as oxaliplatin, irinotecan, fluorouracil plus leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel, for the treatment of unresectable pancreatic cancer, the antitumor activity and overall survival in patients with pancreatic cancer have dramatically improved. These advances in intensive chemotherapy have led to the possibility of conversion of unresectable disease to resectable disease, and it has been reported that more than 20% of pancreatic cancer patients with unresectable locally advanced disease at diagnosis undergo successful conversion surgery after FOLFIRINOX therapy...
May 2018: Journal of Hepato-biliary-pancreatic Sciences
keyword
keyword
66462
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"